Cargando…

Evaluation of immune-biomarker expression in high-grade soft-tissue sarcoma: HLA-DQA1 expression as a prognostic marker

High-grade soft-tissue sarcoma (STS) is a highly malignant neoplasm with a poor overall prognosis. Numerous prognostic factors determine tumor progression and patient outcomes. Various immune-associated cells identified in the tumor microenvironment have important roles in various tumor types. The p...

Descripción completa

Detalles Bibliográficos
Autores principales: Bae, Jung Yun, Choi, Kyung Un, Kim, Ahrong, Lee, So Jung, Kim, Kyungbin, Kim, Jee Yeon, Lee, In Sook, Chung, So Hak, Kim, Jeung Il
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517476/
https://www.ncbi.nlm.nih.gov/pubmed/32989386
http://dx.doi.org/10.3892/etm.2020.9225
_version_ 1783587234538061824
author Bae, Jung Yun
Choi, Kyung Un
Kim, Ahrong
Lee, So Jung
Kim, Kyungbin
Kim, Jee Yeon
Lee, In Sook
Chung, So Hak
Kim, Jeung Il
author_facet Bae, Jung Yun
Choi, Kyung Un
Kim, Ahrong
Lee, So Jung
Kim, Kyungbin
Kim, Jee Yeon
Lee, In Sook
Chung, So Hak
Kim, Jeung Il
author_sort Bae, Jung Yun
collection PubMed
description High-grade soft-tissue sarcoma (STS) is a highly malignant neoplasm with a poor overall prognosis. Numerous prognostic factors determine tumor progression and patient outcomes. Various immune-associated cells identified in the tumor microenvironment have important roles in various tumor types. The present study was performed to evaluate the expression of immune-associated genes and to elucidate the association between these genes and the prognosis in high-grade STS. A total of 12 formalin-fixed, paraffin-embedded tissue samples of high-grade STS were subjected to gene expression analysis using the NanoString nCounter(®) System and another 35 samples were used for immunohistochemistry. For comparative analysis, the patients were divided into two groups according to overall survival (OS). The expression levels of 770 genes were first analyzed using the nCounter(®) PanCancer Immune Profiling Panel. Immunohistochemistry was then performed for the most significantly altered genes. Subsequently, the association between gene expression and prognosis of high-grade STS was evaluated. Of the 770 immune-associated genes analyzed, several genes were identified as being differentially expressed between the two groups. Based on gene expression levels and fold change, 13 representative genes were identified; 7 of the 13 candidate genes (C3, CD36, DOCK9, FCER2, FOS, HLA-DRB4 and NCAM1) were significantly overexpressed in the poor prognosis group, while the other 6 immune-associated genes (BIRC5, DUSP4, FOXP3, HLA-DQA1, HLA-DQB1 and LAG3) were increased in the good prognosis group. By immunohistochemistry, the expression of the 13 immune-associated genes was confirmed to be significantly different between the two groups. Expression of HLA-DQA1, HLA-DQB1 and HLA-DRB4 was observed in 74.3, 34.3 and 48.6% of tumors, respectively. HLA-DQA1 and HLA-DQB1 were significantly decreased, whereas HLA-DRB4 was significantly increased in the poor prognosis group. Of note, expression of HLA-DQA1 was associated with a significantly longer OS (P=0.028). In conclusion, HLA-DQA1 expression was significantly associated with long-term survival and may therefore be an immune biomarker for good prognosis in high-grade STS.
format Online
Article
Text
id pubmed-7517476
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-75174762020-09-27 Evaluation of immune-biomarker expression in high-grade soft-tissue sarcoma: HLA-DQA1 expression as a prognostic marker Bae, Jung Yun Choi, Kyung Un Kim, Ahrong Lee, So Jung Kim, Kyungbin Kim, Jee Yeon Lee, In Sook Chung, So Hak Kim, Jeung Il Exp Ther Med Articles High-grade soft-tissue sarcoma (STS) is a highly malignant neoplasm with a poor overall prognosis. Numerous prognostic factors determine tumor progression and patient outcomes. Various immune-associated cells identified in the tumor microenvironment have important roles in various tumor types. The present study was performed to evaluate the expression of immune-associated genes and to elucidate the association between these genes and the prognosis in high-grade STS. A total of 12 formalin-fixed, paraffin-embedded tissue samples of high-grade STS were subjected to gene expression analysis using the NanoString nCounter(®) System and another 35 samples were used for immunohistochemistry. For comparative analysis, the patients were divided into two groups according to overall survival (OS). The expression levels of 770 genes were first analyzed using the nCounter(®) PanCancer Immune Profiling Panel. Immunohistochemistry was then performed for the most significantly altered genes. Subsequently, the association between gene expression and prognosis of high-grade STS was evaluated. Of the 770 immune-associated genes analyzed, several genes were identified as being differentially expressed between the two groups. Based on gene expression levels and fold change, 13 representative genes were identified; 7 of the 13 candidate genes (C3, CD36, DOCK9, FCER2, FOS, HLA-DRB4 and NCAM1) were significantly overexpressed in the poor prognosis group, while the other 6 immune-associated genes (BIRC5, DUSP4, FOXP3, HLA-DQA1, HLA-DQB1 and LAG3) were increased in the good prognosis group. By immunohistochemistry, the expression of the 13 immune-associated genes was confirmed to be significantly different between the two groups. Expression of HLA-DQA1, HLA-DQB1 and HLA-DRB4 was observed in 74.3, 34.3 and 48.6% of tumors, respectively. HLA-DQA1 and HLA-DQB1 were significantly decreased, whereas HLA-DRB4 was significantly increased in the poor prognosis group. Of note, expression of HLA-DQA1 was associated with a significantly longer OS (P=0.028). In conclusion, HLA-DQA1 expression was significantly associated with long-term survival and may therefore be an immune biomarker for good prognosis in high-grade STS. D.A. Spandidos 2020-11 2020-09-18 /pmc/articles/PMC7517476/ /pubmed/32989386 http://dx.doi.org/10.3892/etm.2020.9225 Text en Copyright: © Bae et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Bae, Jung Yun
Choi, Kyung Un
Kim, Ahrong
Lee, So Jung
Kim, Kyungbin
Kim, Jee Yeon
Lee, In Sook
Chung, So Hak
Kim, Jeung Il
Evaluation of immune-biomarker expression in high-grade soft-tissue sarcoma: HLA-DQA1 expression as a prognostic marker
title Evaluation of immune-biomarker expression in high-grade soft-tissue sarcoma: HLA-DQA1 expression as a prognostic marker
title_full Evaluation of immune-biomarker expression in high-grade soft-tissue sarcoma: HLA-DQA1 expression as a prognostic marker
title_fullStr Evaluation of immune-biomarker expression in high-grade soft-tissue sarcoma: HLA-DQA1 expression as a prognostic marker
title_full_unstemmed Evaluation of immune-biomarker expression in high-grade soft-tissue sarcoma: HLA-DQA1 expression as a prognostic marker
title_short Evaluation of immune-biomarker expression in high-grade soft-tissue sarcoma: HLA-DQA1 expression as a prognostic marker
title_sort evaluation of immune-biomarker expression in high-grade soft-tissue sarcoma: hla-dqa1 expression as a prognostic marker
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517476/
https://www.ncbi.nlm.nih.gov/pubmed/32989386
http://dx.doi.org/10.3892/etm.2020.9225
work_keys_str_mv AT baejungyun evaluationofimmunebiomarkerexpressioninhighgradesofttissuesarcomahladqa1expressionasaprognosticmarker
AT choikyungun evaluationofimmunebiomarkerexpressioninhighgradesofttissuesarcomahladqa1expressionasaprognosticmarker
AT kimahrong evaluationofimmunebiomarkerexpressioninhighgradesofttissuesarcomahladqa1expressionasaprognosticmarker
AT leesojung evaluationofimmunebiomarkerexpressioninhighgradesofttissuesarcomahladqa1expressionasaprognosticmarker
AT kimkyungbin evaluationofimmunebiomarkerexpressioninhighgradesofttissuesarcomahladqa1expressionasaprognosticmarker
AT kimjeeyeon evaluationofimmunebiomarkerexpressioninhighgradesofttissuesarcomahladqa1expressionasaprognosticmarker
AT leeinsook evaluationofimmunebiomarkerexpressioninhighgradesofttissuesarcomahladqa1expressionasaprognosticmarker
AT chungsohak evaluationofimmunebiomarkerexpressioninhighgradesofttissuesarcomahladqa1expressionasaprognosticmarker
AT kimjeungil evaluationofimmunebiomarkerexpressioninhighgradesofttissuesarcomahladqa1expressionasaprognosticmarker